In case of anastrozole-related hallucinations,can switching to letrozole be a treatment option? A case report and literature review

Abstract

Arthralgia, myalgia, paresthesia, reduced bone mineral density, vasomotor side effects including hot flashes and night sweats, genitourinary symptoms including decreased libido, vaginal dryness and dyspareunia are common side effects of aromatase inhibitors. Unlike the common side effects, the information on neurological side effects like hallucination of aromatase inhibitor was limited in literature cases. Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer. A 62-year-old female patient with breast cancer developed repetitive hallucinations on the following days of anastrozole initiation. There was no other significant finding in the differential diagnosis of hallucination. Neurological symptoms disappeared after termination of anastrozole. The patient had no neuropsychiatric complaints during letrozole treatment. We aimed to emphasize that neurological side effect like hallucination may rarely occur during the treatment of anastrozole and in case of aromatase inhibitor-related hallucinations, switching to another aromatase inhibitor (letrozole) can be a treatment option.

Keywords

Anastrozole aromatase inhibitor hallucination letrozole

Get full access to this article

View all access options for this article.

References

Dowsett

Cuzick

Ingle

et al.

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509–518.

Smith

Dowsett

. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431–2442.

Burstein

Termin

Anderson

et al.

Adjuvant endocrine therapy for women with hormone-receptor positive breast cancer: American Society Of Clinical Oncology Clinical Practice Guideline focused update. J Clin Oncol 2014; 32: 2255–2269.

Henry

Azzouz

Desta

et al.

Predictors of aromatase ınhibitor discontinuation as a result of treatment-emergent symptoms in earlystage breast cancer. J Clin Oncol 2012; 30: 936–942.

Lintermans

Neven

. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin Drug Saf 2015; 14: 1201–1211.

Bonneterre

Thürlimann

Robertson

et al.

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study [erratum in 2012;30:343]. J Clin Oncol 2000; 18: 3748–3757.

Cardoso

Costa

Norton

et al.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)y. Ann Oncol 2014; 25: 1871–1888.

Mauri

Pavlidis

Polyzos

et al.

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98: 1285–1291.

Finn

Martin

Rugo

et al.

Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925–1936.

10.

Hortobagyi

Stemmer

Burris

et al.

Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738–1748.

11.

Goetz

Toi

Campone

et al.

MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35: 3638–3846.

12.

Geisler

Haynes

Anker

et al.

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751–757.

13.

Chien

Goss

. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24: 5305–5312.

14.

Crew

Greenlee

Capodice

et al.

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877–3883.

15.

Sherwin

. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24: 133–151.

16.

Jenkins

Ambroisine

Atkins

et al.

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008; 9: 953–961.

17.

Schilder

Seynaeve

Beex

et al.

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010; 28: 1294–1300.

18.

Phillips

Ribi

Sun

et al.

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19: 388–395.

19.

Jenkins

Shilling

Fallowfield

et al.

Does hormone therapy for the treatment of breast cancer have a detrimental eff ect on memory and cognition? A pilot study. Psychooncology 2004; 13: 61–66.

20.

Kumar

Soren

Chaudhury

. Hallucinations: etiology and clinical implications. Ind Psychiatry J 2009; 18: 119–119.

21.

Nicoletti

Patti

Ferrara

et al.

Comparative effects of estrogens and prolactin on nigral and striatal GAD activity. Brain Res 1982; 232: 238–241.